GlassScriptPhysician profile
Saul Lanes
NPI 1962498915
$2,051.64
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $681.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $657.89 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $370.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.47 | 2019-2020 | |
| Mylan Specialty L.P. | $221.22 | 2019-2020 | |
| Insmed, INC. | $118.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $112.24 | 2019 | |
| Vapotherm INC | $67.28 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $58.68 | 2019-2020 | |
| Genzyme Corporation | $43.43 | 2019 | |
| Genentech USA, INC. | $39.17 | 2019 | |
| Electromed, INC. | $17.77 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.55 | 2020 | |
| Optinose US, INC. | $16.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Lanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.